NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Breast Cancer

Interventions: trastuzumab [Herceptin]

Countries: Austria, Belgium, Germany, Hungary, Italy, Poland, Spain, Sweden

This is a single cohort observational safety study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the usual clinical practice are planned for the study. Data will be collected from centre's medical records for up to 5 years or death.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* All patients who are considered candidates to receive Herceptin for this indication

Exclusion Criteria:

* Patients for whom Herceptin is contraindicated

Locations (205)

Graz, Austria
Graz, Austria
Klagenfurt, Austria
Leoben, Austria
Linz, Austria
Rankweil, Austria
Salzburg, Austria
Sankt Veit an der Glan, Austria
Steyr, Austria
Vienna, Austria
Vienna, Austria
Vienna, Austria
Vienna, Austria
Vöcklabruck, Austria
Wels, Austria
Antwerp, Belgium
Baudour, Belgium
Brasschaat, Belgium
Bruges, Belgium
Brussels, Belgium
Brussels, Belgium
Brussels, Belgium
Edegem, Belgium
Kortrijk, Belgium
Liège, Belgium
Namur, Belgium
Ottignies, Belgium
Roeselare, Belgium
Sint-Niklaas, Belgium
Turnhout, Belgium
+ 175 more on CT.gov